A Phase 2 interventional study of Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC) in Melanoma, sponsored by Bayer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-31.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing dacarbazine in Melanoma — none open to participants now, 1 under way, none of them phase 3. Dacarbazine · Melanoma.
Among the 30 studies testing dacarbazine in Melanoma, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2005, is one of 14 in phase 2, and was the 11th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 30 studies testing dacarbazine in Melanoma is open now. The open studies under Melanoma, anywhere →
Dacarbazine: first FDA approval 1975 (DTIC-DOME). What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 18 · Phase 3 6 · Phase 4 1
First in 1997; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 64 across the 25 interventional studies. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 30 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing dacarbazine in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC). DTIC is the current standard chemotherapy drug given for melanoma that has spread through the body. Although this drug can be effective on its own and is generally well tolerated, not all patients will benefit, so there is a need to test new drugs and drug combinations for treating melanoma.
Issues on "Safety" outcomes are addressed in the Adverse Event section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
Drug page: Dacarbazine
Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
Overall Best Response
Best Overall Response (BOR): Best tumor response achieved during or within 30 days after active therapy confirmed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR): The disappearance of all target and non-target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD was defined as steady state of disease, PD was defined as an increase of at least 20% increase in the sum of the LD of target lesions or appearance of new lesions.
Time frame: during or within 30 days after active therapy
Progression-free Survival
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.
Time frame: from start of treatment until progression or death before progression (median 259 days)
Percentage of Subjects With Progression-free Survival at Specific Time-points
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.
Time frame: from start of treatment until progression or death before progression after 3, 6 and 12 months
Overall Survival
Overall Survival was the number of days from the date that combination treatment started until the date of death.
Time frame: from start of treatment until death (median 259 days)
Duration of Response
Duration of Response was assessed in subjects who showed a Partial Response (PR) or Complete Response (CR). It was defined as the time from the first documented objective response to Progressive Disease (PD), or death if before documented progression. Duration of response for subjects who have not progressed or died at the time of analysis was censored at the date of last tumor assessment.
Time frame: from confirmed Complete Response (CR) or Partial Response (PR) until Progressive Disease (PD) (median 259 days)
Duration of Complete Response
Duration of complete response was the number of days from the date that a complete response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).
Time frame: from confirmed CR until PD (median 259 days)
Duration of Partial Response
Duration of partial response was the number of days from the date that a partial response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).
Time frame: from confirmed PR until PD (median 259 days)
Disease Control (DC)
DC was defined as the total number of subjects whose best response was not progressive disease (PD) (total number of CRs + total number of PRs + total number of Stable Diseases (SD)). The DC at specific time points could also be calculated as the total number of subjects whose response was not PD at that time point.
Time frame: after start of treatment, at 6 months and 12 months
Duration of Stable Disease
Duration of Stable Disease (DSD), defined as the time from the first documented objective evidence of Stable Disease (SD) to disease progression (DP) or death if death occurred before DP, was assessed in subjects who showed SD as best response. DSD for subjects who had not progressed or died was censored at the date of last tumor assessment.
Time frame: from start of therapy to PD, only in non-responders (median 259 days)
Time to Response
Time to Response in subjects who achieved an objective response (PR or CR with confirmation) was measured from the date of starting study combination treatment until the earliest date that the response was first documented.
Time frame: start of therapy to confirmed CR or PR (median 259 days)
Time to Progression
Time to Progression was the number of days from the start of therapy to progression (if patient progressed then censored=no) or to the last observation at which the patient was known to have not progressed, that is, the last observation with a best response of CR, PR, or SD.
Time frame: From start of treatment until progression (median 259 days)
This study had a 2-stage Simon optimal design consisting of 30 subjects in the first stage and 52 subjects in the second stage for a planned total of 82 subjects. Actually a total of 96 subjects were enrolled and 83 were treated; 32 in the 1st stage and 51 in the second stage. The study was conducted at 8 centers in the UK and 4 centers in France.
| Milestone | Sorafenib + Dacarbazine |
|---|---|
| Started | 83 |
| First stage of simon optimal design | 32 |
| Second stage of simon optimal design | 51 |
| Completed | 78 |
| Not completed | 5 |
| Withdrew: Death | 2 |
| Withdrew: Study terminated by sponsor | 3 |
| Milestone | Sorafenib + Dacarbazine |
|---|---|
| Started | 78 |
| Completed | 59 |
| Not completed | 19 |
| Withdrew: Death | 17 |
| Withdrew: Study terminated by sponsor | 2 |
| Milestone | Sorafenib + Dacarbazine |
|---|---|
| Started | 59 |
| Completed | 0 |
| Not completed | 59 |
| Withdrew: Death | 46 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Study terminated by sponsor | 12 |
Best Overall Response (BOR): Best tumor response achieved during or within 30 days after active therapy confirmed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR): The disappearance of all target and non-target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD was defined as steady state of disease, PD was defined as an increase of at least 20% increase in the sum of the LD of target lesions or appearance of new lesions.
| participants | Sorafenib + Dacarbazine |
|---|---|
| Overall response (CR+PR) | 10 |
| Complete response (CR) | 1 |
| Partial response (PR) | 9 |
| Stable disease (SD) | 31 |
| Progressive disease (PD) | 34 |
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.
| days | Sorafenib + Dacarbazine |
|---|---|
| Progression-free Survival | 102 (83 to 134) |
Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.
| percentage of participants | Sorafenib + Dacarbazine |
|---|---|
| PFS at month 3 | 56.63 |
| PFS at month 6 | 33.73 |
| PFS at month 12 | 10.84 |
Overall Survival was the number of days from the date that combination treatment started until the date of death.
| days | Sorafenib + Dacarbazine |
|---|---|
| Overall Survival | 259 (237 to 322) |
Duration of Response was assessed in subjects who showed a Partial Response (PR) or Complete Response (CR). It was defined as the time from the first documented objective response to Progressive Disease (PD), or death if before documented progression. Duration of response for subjects who have not progressed or died at the time of analysis was censored at the date of last tumor assessment.
| days | Sorafenib + Dacarbazine |
|---|---|
| Duration of Response | 327 (99 to 628) |
Duration of complete response was the number of days from the date that a complete response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).
| days | Sorafenib + Dacarbazine |
|---|---|
| Duration of Complete Response | 420 |
Duration of partial response was the number of days from the date that a partial response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).
| days | Sorafenib + Dacarbazine |
|---|---|
| Duration of Partial Response | 255 (231 to 448) |
DC was defined as the total number of subjects whose best response was not progressive disease (PD) (total number of CRs + total number of PRs + total number of Stable Diseases (SD)). The DC at specific time points could also be calculated as the total number of subjects whose response was not PD at that time point.
| participants | Sorafenib + Dacarbazine |
|---|---|
| DC based on overall best response | 41 |
| DC at 6 months | 38 |
| DC at 12 months | 38 |
Duration of Stable Disease (DSD), defined as the time from the first documented objective evidence of Stable Disease (SD) to disease progression (DP) or death if death occurred before DP, was assessed in subjects who showed SD as best response. DSD for subjects who had not progressed or died was censored at the date of last tumor assessment.
| days | Sorafenib + Dacarbazine |
|---|---|
| Duration of Stable Disease | 93 (77 to 112) |
Time to Response in subjects who achieved an objective response (PR or CR with confirmation) was measured from the date of starting study combination treatment until the earliest date that the response was first documented.
| days | Sorafenib + Dacarbazine |
|---|---|
| Time to Response | 48 (41 to 87) |
Time to Progression was the number of days from the start of therapy to progression (if patient progressed then censored=no) or to the last observation at which the patient was known to have not progressed, that is, the last observation with a best response of CR, PR, or SD.
| days | Sorafenib + Dacarbazine |
|---|---|
| Time to Progression | 102 (88 to 139) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sorafenib + Dacarbazine | — | 40/83 (48.2%) | 82/83 (98.8%) |
| Event | Sorafenib + Dacarbazine |
|---|---|
| Death not associated with CTAE term, disease progression nosGeneral disorders | 7/83 |
| PlateletsBlood and lymphatic system disorders | 5/83 |
| Pain, abdomen nosGeneral disorders | 5/83 |
| FeverGeneral disorders | 4/83 |
| Thrombosis/thrombus/embolismVascular disorders | 4/83 |
| HemoglobinBlood and lymphatic system disorders | 3/83 |
| FatigueGeneral disorders | 3/83 |
| LeukocytesBlood and lymphatic system disorders | 2/83 |
| NeutrophileBlood and lymphatic system disorders | 2/83 |
| Cardiac arrhythmia - otherCardiac disorders | 2/83 |
| Event | Sorafenib + Dacarbazine |
|---|---|
| FatigueGeneral disorders | 51/83 |
| ConstipationGastrointestinal disorders | 44/83 |
| DiarrheaGastrointestinal disorders | 43/83 |
| NeutrophilsBlood and lymphatic system disorders | 42/83 |
| NauseaGastrointestinal disorders | 38/83 |
| Hand-foot skin reactionSkin and subcutaneous tissue disorders | 37/83 |
| Rash/desquamationSkin and subcutaneous tissue disorders | 33/83 |
| PlateletsBlood and lymphatic system disorders | 24/83 |
| VomitingGastrointestinal disorders | 24/83 |
| Pain, abdomen nosGeneral disorders | 24/83 |
| Age, Continuous(years) | Sorafenib + Dacarbazine |
|---|---|
| Mean | 53.5 (25 to 78) |
| Sex: Female, Male(Participants) | Sorafenib + Dacarbazine |
|---|---|
| Female | 33 |
| Male | 50 |
| Clinical disease status(participants) | Sorafenib + Dacarbazine |
|---|---|
| Missing | 6 |
| Stable disease | 3 |
| Progressive disease | 74 |
| Disease stage (AJCC)(participants) | Sorafenib + Dacarbazine |
|---|---|
| Missing | 1 |
| M1a Distant subcutaneous or lymphnode metastases | 4 |
| M1b Lung metastases | 12 |
| M1c All other visceral metastases | 66 |
| ECOG status(participants) | Sorafenib + Dacarbazine |
|---|---|
| Missing | 3 |
| 0 | 52 |
| 1 | 28 |
| Histology(participants) | Sorafenib + Dacarbazine |
|---|---|
| Missing | 24 |
| Malignant melanoma | 4 |
| Superfical spreading | 24 |
| Nodular | 29 |
| Acral lentiginous | 2 |
| Lactate dehydrogenase(participants) | Sorafenib + Dacarbazine |
|---|---|
| Missing | 3 |
| < Upper Limit of Normal (ULN=325 U/L) | 43 |
| >= ULN but < 10 percent above ULN | 11 |
| >= 10 percent above the ULN | 26 |
| Mean time from diagnosis(days) | Sorafenib + Dacarbazine |
|---|---|
| Mean | 1280 (9 to 5344) |
The record gives a start of Apr 2005, a primary completion of Jun 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dacarbazine